Sources revealed than US President Donald Trump's expected executive order focused on drug pricing may not be ready for a few weeks, CNBC reported Tuesday.
People familiar with the matter noted that the current proposals do not seek major changes such as allowing Medicare to negotiate drug prices, focusing instead on policies such as value-based pricing.
"[There is a] general recognition that the Trump threat to regulate drug prices in a harmful way is receding," Leerink analyst Geoff Porges commented, adding "the light at the end of the tunnel is now in the tunnel!"
Meanwhile, FDA Commissioner Scott Gottlieb has called for the agency to attempt to increase drug affordability by increasing competition.
The agency has also signalled willingness to approve treatmetns based on genetic signatures instead of for specific conditions, as indicated by the recent approval of Merck & Co.'s Keytruda for microsatellite instability-high or mismatch repair deficient cancers.
"Gottlieb endorsing genetically defined drug approvals...particularly in oncology is very positive," Porges explained, noting that such a move would benefit drugmakers such as Epizyme, Loxo Oncology, Merck and Vertex Pharmaceuticals.
To read more NewsPoints articles, click here.